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Introduction
Idiopathic thrombocytopenic purpura (ITP) is an acquired immune-mediated disease defined as a transient or persistent decrease of platelet count [1, 2] . The decreased platelet count in ITP is associated with an increased rate of bleeding, hemorrhage-related outcomes [3] and abnormal platelet activity [4] . The global incidence rate for ITP in adults is estimated to be 1.6-3.9/100 000 persons with incidence rates estimated at 5.6-20/100 000 population [5] . The incidence reported in the UK is particularly high, with an estimated incidence of 3.9/100 000 persons and a prevalence of 50/100 000 population [6, 7] .
It has been well established that mortality is higher within the ITP cohort than the general population [8, 9] . Previous population-based studies have also identified a comparatively higher incidence of diabetes, acute/chronic renal failure, leukemia and Hodgkin's disease within the ITP cohort [8] . An increased incidence of any vascular event (incidence rate ratio [IRR], 1.0; 95% confidence interval [CI] 1.41-2.05) and particularly unstable angina, ischemic stroke and transient ischemic attack (TIA), have been identified in a cohort study conducted in the USA utilizing insurance data [8] . However, there has been conflicting evidence surrounding the nature and strength of the association between myocardial infarction (MI) and ITP [8, 10] . The only study conducted in the UK looked at multiple conditions and did not account for the time to event or adjust for important confounders [10] .
The pathophysiology by which ITP affects cardiovascular disease is unclear. Platelet destruction releases humoral factors and platelet microparticles (PMPs) [11] , which are elevated in ITP patients [12] . PMPs induce thrombin and coagulation activations, which may increase thrombotic outcomes [13] . ITP patients often have elevated proinflammatory cytokines, suggesting an inflammatory etiology [14, 15] . Inflammatory activity may also affect coagulation states, which could put individuals at risk of thrombotic events [16] .
The mainstay of treatment for ITP (based on severity deemed by platelet count) is the use of glucocorticosteroids. The majority of ITP cases are steroid responsive and total remission can be achieved in 33% of cases [17] . Partial or total splenectomy is an alternative treatment for adult patients not responding to glucocorticoid therapy, with remission of ITP in two-thirds of cases [18] . Splenectomy is not without risk, and even the laparoscopic approach bears a significant risk of surgical complications (9.6%) [18] . It has been identified that ITP patients who undergo splenectomy are at a higher risk of venous thromboembolic events [19] . The pathophysiological link is unclear. There is evidence to suggest that splenectomy may lead to both thrombocytosis and an increased number of damaged red cells. This induces a hypercoagulable state with increase thrombotic risk [20] [21] [22] . Post-splenectomy patients have been shown to have even higher levels of cellular microparticles (C-MPs), which further promote hypercoagulability [23] .
This study aims to explore the association between ITP and cardiovascular disease, as well as attempt to identify the impact of splenectomy on this association.
Methods

Study design
This was a population-based, retrospective open cohort study in which patients diagnosed with ITP were compared with healthy controls matched by age, sex, body mass index (BMI) and smoking status. The Health Improvement Network (THIN) has been demonstrated to be broadly representative of the UK population [24] .
Data source
The THIN database comprises UK electronically recorded medical records in primary care, with the purpose of the database being to encourage research in order to improve healthcare delivery. The THIN database comprises 675 UK general practices, compiling data on over 14 million patients; over 3.6 million of the actively registered patients are broadly representative of the UK population [25] . Patient information is entered into Vision patient record software, which uses Read code data (Clinical code) [26] , rather than the International Classification of Diseases (ICD) codes. The Vision software also captures laboratory results as well as some British National Formulary drug prescription records [27] . The University of Birmingham holds a data sharing agreement with IMSHealth (the providers of THIN) to allow for data to be used for research under the Data Protection Act (1998). [28] .
Study population
The study population consisted of patients diagnosed with ITP (exposed) and controls not diagnosed with ITP (unexposed) during the study period from 1 January 1996 to 1 September 2015.
Individual practices were eligible for inclusion in the study from the later of the following two dates to ensure that the practice was making full use of their system and not under-recording important outcomes: 1 year after the date the practice system was installed; and the practice's acceptable mortality recording (AMR) date. Individual patients were eligible for inclusion from the latest of the following dates to ensure that there was sufficient time for baseline data on comorbidities to have been recorded: the date the practice became eligible for inclusion; and a year after registration with the practice to allow for the recording of comorbidities.
Selection criteria
Follow-up start date for an indexed patient (index date) in the exposed group was set at first documentation of ITP once a patient was eligible to take part in the study (newly diagnosed patients/incident cases) or the date a patient became eligible to take part in the study, if they already had a diagnosis of ITP (patients with an existing diagnosis/prevalent cases) ( Figure S1 ). The same index date was assigned for their matched corresponding unexposed patients to mitigate immortality time bias. Both the exposed group (ITP) and unexposed group (control) were followed-up from the index date until the first of the following events (exit date): patient died; patient left practice; last data collection from practice; study end date; patient diagnosed with cardiovascular disease (stroke or ischemic heart disease, myocardial infarction and angina).
Patients were excluded from the study if they had a diagnosis of cardiovascular disease (CVD) prior to the index date of the study. Individuals were included in the exposed group if they had a recorded diagnosis of ITP (Table S1 ) using clinical codes (https://digital.nhs.uk/artic le/1104/Read-Codes). ITP codes were validated from previous studies where read codes were used to identify exposed ITP patients [6, 7] . In the UK, the diagnosis of ITP is made by a hematologist in a secondary/tertiary setting, which is then relayed to the general practitioner (GP), whose responsibility it would be to record this on the patient's electronic medical record. The diagnostic criteria for identifying ITP in the UK secondary care setting are based on the 'British Committee for Standards in Hematology' guideline. [29] A record of splenectomy also identified through clinical codes (Table S1) was also recorded at this point. Each ITP patient was then matched to four control patients in the unexposed cohort who were randomly selected from the same general practice. Controls were individually matched to cases on age at index date (to within 2 years), BMI (to within 2 kg m 2 ), smoking status and gender.
Outcomes
The primary outcome was the development of a large vessel atherosclerotic/thrombotic cardiovascular event (ischemic heart disease, heart failure and stroke/TIA during the observation period as well as a composite outcome of all three) identified through clinical codes (Table S3) . Recording of CVD is accurate in UK primary care because there is a mandatory requirement for maintaining a register for cardiovascular disease and incentive payments are made for identification and management of CVD [30] .
Covariates Well-known covariates that impact on the development of cardiovascular disease were identified in the study population baseline data. These included hypertension, diabetes mellitus, inherited thrombophilias, comorbidity identified through the Charlson comorbidity index, and the use of lipid lowering medications, antiplatelet agent medications and warfarin medications that were identified through clinical codes inputted by GPs in primary care (Table S2) .
Statistical analysis plan
Baseline characteristics were descriptively compared between the groups. Comparison was assessed using the chi-squared test (sex, Townsend deprivation score, smoking status, hypertension, diabetes mellitus, inherited thrombophilias, Charlson comorbidity index, the use of lipid lowering medications, antiplatelet agent medications, warfarin medications), Student's t-test (age and BMI) or Mann-Whitney U-test (person-years).
An estimated incidence rate ratio was calculated for each outcome. Then adjusted incidence rate ratios were calculated using Poisson regression adjusting for individual patient covariates (age, sex, Townsend deprivation score, smoking status, hypertension, diabetes mellitus, inherited thrombophilias, Charlson comorbidity index, and the use of lipid lowering medications, antiplatelet agent medications and warfarin medications to account for any variation in consultation practice). BMI was treated as a categorical variable to address missing values. Incidence rate ratios were calculated with 95% confidence and a statistical significance threshold of P < 0.05.
As a secondary analysis, we also assessed the impact of splenectomy on patient outcomes. We looked at the risk of cardiovascular disease within the ITP patients stratified by those who had splenectomy and those who did not. This allowed for analysis of the isolated impact of splenectomy in the exposed group.
In a sensitivity analysis, we restricted the investigation of occurrence of cardiovascular disease to only patients with incident diagnoses of ITP and their respective matched controls during the study period to account for survival bias that may underestimate or overestimate the effect size.
All analysis was conducted using Stata v14.0 software. The THIN data collection scheme received multicenter research ethics committee (MREC) approval in 2003, with scientific committee approval of this particular study in March 2017 (SRC 17THIN024) from 'IMSHealth' (data provider).
Results
Baseline characteristics
A total of 6591 patients with ITP were identified in the THIN database and matched to 24 275 controls (on 1 : 4 ratio). The mean length of follow-up in the ITP and control populations, was 5.6 years (standard deviation [SD] 4.5 years) and 6 years (SD 4.6 years), respectively.
Mean patient age within the ITP cohort was 48.4 years (SD 19.1 years), with significantly more women than men (58.6% vs. 41.3%, respectively). In general, there was a significant difference in the proportion of patients with diabetes and lipid-lowering medications between the ITP and control cohort. Baseline characteristics are described in further detail in Table 1 (missing values are in Table S6 ). In the ITP group, there were 506 (7.6%) patients with splenectomy at study entry and an additional 162 splenectomies (in total 668; 10.1%) during the follow-up period. Three hundred and fifty-three (5.4%) patients were on active treatment with steroids at baseline.
Association between cardiovascular disease and ITP
During the observation period 392 (5.9%) and 1114 (4.5%) patients in the ITP and control groups, respectively, experienced a cardiovascular event. The incidence rate was 11 and 8 per 1000 person-years, respectively. The adjusted incidence rate ratio of all cardiovascular disease was found to be significantly higher in the ITP cohort compared with the control cohort (adjusted IRR, 1.38; 95% CI, 1.23-1.55; P < 0.001). Further sub-analysis was carried out to compare the incidence of ischemic heart disease, stroke/TIA and heart failure separately in these cohorts. Following sub-analysis, the ITP cohort demonstrated increased adjusted incidence rate ratios of ischemic heart disease (IRR, 1.21; 95% CI, 1.01-1.44; P = 0.034), stroke or TIA (IRR, 1.39; 95% CI, 1.17-1.66; P < 0.001) and heart failure or left ventricular dysfunction (IRR, 1.42; 95% CI, 1.12-1.81; P = 0.004) ( Table 2 ).
The impact of splenectomy on cardiovascular disease in the ITP cohort ITP patients with splenectomy at baseline had an increased adjusted (adjusted for age, sex, Townsend deprivation score, smoking status, hypertension, diabetes mellitus and the use of lipid-lowering medications, steroid use, Charlson comorbidity index, antiplatelets, inherited thrombophilias, and warfarin use) incidence rate ratio of cardiovascular disease compared with ITP patients who did not have splenectomy (adjusted, IRR 1.69; 95% CI, 1.22-2.34; P = 0.001). Active steroid treatment at baseline also had an increased incidence rate ratio for cardiovascular disease compared with ITP patients who did not have steroid treatment (adjusted IRR, 1.49; 95% CI, 1.07-2.08; P = 0.017).
Additional analysis
Results of an analysis also adjusting for consultation rate showed similar results (Table S4) , with an adjusted incidence rate ratio for cardiovascular disease significantly greater in ITP patients (1.49; 95% CI, 1.33-1.67). An analysis restricted to incident ITP patients also showed concurrent results (Table S5 ). The adjusted incidence rate ratio for cardiovascular disease was significantly greater in ITP patients compared with controls in incident-only cases (1.38; 95% CI, 1.15-1.66).
Discussion
Summary of key results
This study found that individuals with ITP were at a higher risk of developing all types of CVD (adjusted IRR, 1.38; 95% CI, 1.23-1.55; P < 0.001) when compared with individuals without ITP over the observation period. These findings remained once adjusted for clinically significant risk factors for developing CVD. We also demonstrated that patients who have undergone splenectomy were at even further increased risk of developing CVD when compared with the ITP population at baseline who had not undergone splenectomy (adjusted IRR, 1.69; 95% CI, 1.22-2.34; P = 0.001).
Compared with current literature
The results of this study build on the current literature surrounding ITP and CVD risk. ITP is an autoimmune condition characterized by a low platelet count and bleeding, but conversely, individuals with ITP may show an increased thrombotic and atherosclerotic risk [31] hypothesized to be due to PMP cascade. An American epidemiological study has demonstrated some of the significant associations between ITP and TIA (IRR, 1.69; 95% CI, 1.21-2.35), and ITP and stroke (IRR, 2.05; 95% CI, 1.26-3.36), and an insignificant association between ITP and MI (IRR, 0.80; 95% CI, 0.49-1.30) [8] . [10] . The results of this study confirm the findings of the previous studies and address the methodological limitations noted in them.
Though the link between splenectomy and venous thromboembolic events has been explored [20] [21] [22] and hypothesized to be due to a hypercoagulable state, the link between splenectomy and arterial events had not been fully explored. Therefore, the authors believe this is the first study to identify that individuals who have undergone a splenectomy appear to be at an adjusted significantly increased risk of developing CVD (adjusted IRR, 1.69; 95% CI, 1.22-2.34; P = 0.001), even greater than the risk for those who have not undergone a splenectomy procedure.
Study limitations
The findings of this study should be interpreted in the context of its limitations, some of which are inherent to the design of the study. The THIN database is populated using clinical codes classified by general practitioners (GPs) following consultations with individuals. Therefore, the validity of the coding will be affected by the coding practices of individuals, with some patients being misclassified. Every effort was taken to overcome this by selecting a list of multiple clinical codes for ITP and splenectomy to ensure every coding combination was taken into consideration. We did not account for the severity of the disease, which may have given further insight. This may have affected the splenectomy subgroup analysis as individuals who have undergone splenectomy will generally have a more severe form of ITP, which in turn could have increased their risk of developing CVD outcomes. The aims of this study were to identify associations rather than causality due to the nature of the data being analyzed. However, this study has not only been able to demonstrate some important associations regarding ITP and CVD, it has shown that patients who have had a splenectomy as a consequence of ITP may be at increased risk of CVD. On the other hand, when communicating risks to patients or the public, caution is advised given that the absolute risk difference in this young studied population (median age 48.5 years) with a median follow-up of 5.6 years was notably low (3 per 1000 person-years).
Conclusion
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